Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that the UK's second largest retailer, Wal-Mart /ASDA, has launched Heartfelt Plus Natural Cheese incorporating Forbes Medi-Tech's cholesterol-lowering ingredient, Reducol(tm). Heartfelt Plus is the first cheddar cheese in the UK to combine both low-fat and cholesterol-lowering benefits. The product is expected to be on store shelves Thursday, May 11th.
"A first of its kind, Heartfelt Plus cheddar cheese is launching into one of the UK's largest dairy categories with several key competitive advantages," said Charles Butt, President and CEO of Forbes Medi-Tech.
"Heartfelt Plus is competitively priced, low in fat, great tasting and helps lower cholesterol. Wal-Mart / ASDA's launch of the Heartfelt Plus Natural Cheese follows four months after Tesco, the country's largest retailer, chose to launch a range of Reducol(tm)-based dairy products.
Sales of Tesco's range of Reducol(tm)-based products have doubled since January. We believe that the Heartfelt Plus product launch in the cheese category, estimated at over GBP418 million, will help accelerate the adoption of Reducol(tm) throughout Europe."
Natural cheese typically contains a fat content of 30-40 percent. The new Heartfelt Plus cheddar cheese with Reducol(tm) contains a much lower fat content of 12 percent while maintaining the texture and flavor superiority of hard cheese versus competitive alternatives made from vegetable oil.
The Heartfelt Plus cheese retail price is in line with other value-added cheese products at GBP1.98 for a 200g block. Heartfelt Plus is a branded dairy product created by Fayrefield Foods.
Reducol(tm) is a unique ingredient containing plant sterols and stanols, commonly known as phytosterols, or "Sterols". The combination of a prudent diet and consumption of products containing the recommended amount of Reducol(tm) may help consumers lower their cholesterol by up to 24%. Additional information on Reducol(tm) can be found at www.reducol.com
About Wal-Mart / ASDA
ASDA Stores Limited (ASDA) is the UK's second largest supermarket chain with 258 supermarkets located across Great Britain selling a range of grocery and non-grocery items. ASDA was acquired by Wal-Mart Stores, Inc in 1999. Additional information on ASDA can be found at www.asda.co.uk
About Forbes Medi-Tech Inc.
Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of cardiovascular disease (CVD). Our vision is to develop and market products along a treatment continuum that CVD savvy consumers, healthcare professionals and specialized CVD research and healthcare institutions; will identify, recommend and seek. Our business strategy is to develop and commercialize proprietary compounds to address the unmet needs of patients within the cardiovascular disease market.
# # #
For more information, please contact:
Manager, Investor Relations
Telephone: (604) 681-8976
E-mail: [email protected]
NASDAQ and the Toronto Stock Exchange have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. Forbes Medi-Tech ("Forbes" or the "Company") has relied solely on ASDA for the information about Wal-Mart / ASDA provided in this News Release and the Company disclaims any liability with respect to such information. Forbes disclaims responsibility for information contained in any linked or referenced website, and such links and references do not constitute an endorsement by Forbes of those or any other website. Forbes' statement that Heartfelt Plus is the first cheddar cheese in the UK to combine both low-fat and cholesterol-lowering benefits is based solely on research undertaken by the Company, and while believed by the Company to be true, cannot be guaranteed. This News Release contains forward-looking statements regarding future adoption of Reducol(tm), and the Company's strategy and vision, which statements can be identified by the use of forward-looking terminology such as "expected", "believe", "estimated", "will", "may", "up to", "strategy", "vision", "to develop" or comparable terminology referring to future events or results. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including the Company's reliance on Fayrefield Foods for performance and the risk of early termination of either the Company's arrangements with Fayrefield Foods or of Fayrefield Foods' arrangements with Wal-Mart / ASDA; uncertainty regarding market acceptance and demand for products containing Reducol(tm); uncertainty whether the Heartfelt Plus product launch will occur as expected or help accelerate the adoption of Reducol(tm); product development risks; intellectual property risks; manufacturing risks and the Company's dependency on Phyto-Source LP, its manufacturer of Reducol(tm); product liability and insurance risks; uncertainty as to future sales volumes and pricing; the effect of competition; the need for new customers; the need for regulatory approvals, which are uncertain; changes in business strategy or development plans; exchange rate fluctuations; and the Company's need for future funding; any of which could cause actual results to vary materially from current results or the Company's anticipated future results. See the Company's reports filed with the Canadian and U.S. securities regulatory authorities from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this News Release.